- ￥276 - 306
- TargetMol
- T0784
- 2026年07月07日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- CAS号：
13710-19-5
- 规格：
1mLx10mM(inDMSO)/500mg
| 规格： | 1mLx10mM(inDMSO) | 产品价格： | ￥306.0 |
|---|---|---|---|
| 规格： | 500mg | 产品价格： | ￥276.0 |
Product Introduction
Bioactivity
| 名称 | Tolfenamic Acid |
| 描述 | Tolfenamic Acid (GEA 6414) is one of the class of non-steroidal anti-inflammatory drugs (NSAIDs). It is used to treat the symptoms of migraine. |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 49 mg/mL (187.24 mM), Sonication is recommended. 10% DMSO+90% Corn Oil : 2 mg/mL (7.64 mM), Sonication is recommended. |
| 关键字 | Tolfenamic Acid | Inhibitor | inhibit | GEA-6414 | GEA6414 | Cyclooxygenase | COX-2 | COX |
| 相关产品 | Trometamol | Gallic Acid Monohydrate | Naproxen sodium | 4-Aminosalicylic acid | 5-Methylfurfural | Phenylbutazone | Indomethacin | Paradol | Acetaminophen | Diclofenac Potassium | Magnesium sulfate | Phenidone |
| 相关库 | Anti-Cancer Approved Drug Library | Anti-Cancer Active Compound Library | Bioactive Compound Library | Bioactive Compounds Library Max | Failed Clinical Trials Compound Library | Anti-Aging Compound Library | Bitter Compound library | Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Pain-Related Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Drug Library |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验文献： 【1】miR-423-5p-enriched small extracellular vesicles drive periodontal regeneration via Sfrp2+ cell expansion. Bioactive Materials.2025 Nov 29;58:19-32.
μL 体系 2× MasterMix 25 μL 上游 Primer （ 10 μM 1-5 μL 下游 Primer （ 10 μM ） 1-5 μL 模板 lamid DNA ～ 50 ng genomic DNA ～ 1000 ng cDNA ～ 500 ng 粗提液 ～ 2 μL 灭菌蒸馏水至 50 μL PCR 扩增实例： 一、plasmid DNA 扩增 1．提取的质粒 DNA 扩增 以pUC19 质粒为模板扩增 100，250，500
, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020, 395(10229):1033-1034. 6. David J M Wright. Prevention of the cytokine storm in COVID-19. Lancet Infect Dis. 2020. doi: 10.1016/S1473-3099(20)30376-5
技术资料暂无技术资料 索取技术资料
